Last Updated: August 15, 2026

Patent: 10,730,880

✉ Email this page to a colleague

Summary for Patent: 10,730,880

Title:	4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors
Abstract:	Compounds of Formula I: ##STR00001## and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Inventor(s):	Allen; Shelley (Boulder, CO), Boys; Mark Laurence (Boulder, CO), Chicarelli; Mark J. (Boulder, CO), Fell; Jay Bradford (Boulder, CO), Fischer; John P. (Boulder, CO), Gaudino; John (Boulder, CO), Hicken; Erik James (Boulder, CO), Hinklin; Ronald Jay (Boulder, CO), Kraser; Christopher F. (Boulder, CO), Laird; Ellen (Boulder, CO), Robinson; John E. (Boulder, CO), Tang; Tony P. (Boulder, CO), Burgess; Laurence E. (Boulder, CO), Rieger; Robert Andrew (Boulder, CO), Pheneger; Jed (Boulder, CO), Satoh; Yoshitaka (Poway, CA), Leftheris; Katerina (San Diego, CA), Raheja; Raj K. (Poway, CA), Bennett; Brydon L. (San Diego, CA)
Assignee:	Array BioPharma Inc. (Boulder, CO) Celgene Corporation (Summit, NJ)
Application Number:	16/212,493
Patent Claims:	see list of patent claims

Details for Patent 10,730,880

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	ATGAM	lymphocyte immune globulin, anti-thymocyte globulin (equine)	Injection	103676	December 04, 1996	10,730,880	2038-12-06
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997	10,730,880	2038-12-06
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	December 23, 2005	10,730,880	2038-12-06
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	July 29, 2011	10,730,880	2038-12-06
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	June 07, 2016	10,730,880	2038-12-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.